U.S. markets close in 5 hours 32 minutes
  • S&P 500

    3,622.27
    -13.14 (-0.36%)
     
  • Dow 30

    29,886.78
    -159.46 (-0.53%)
     
  • Nasdaq

    12,037.01
    +0.22 (+0.00%)
     
  • Russell 2000

    1,833.09
    -20.44 (-1.10%)
     
  • Crude Oil

    45.36
    +0.45 (+1.00%)
     
  • Gold

    1,809.70
    +5.10 (+0.28%)
     
  • Silver

    23.40
    +0.10 (+0.43%)
     
  • EUR/USD

    1.1909
    +0.0013 (+0.11%)
     
  • 10-Yr Bond

    0.8620
    -0.0200 (-2.27%)
     
  • GBP/USD

    1.3365
    +0.0006 (+0.05%)
     
  • USD/JPY

    104.3300
    -0.1500 (-0.14%)
     
  • BTC-USD

    19,211.09
    -55.55 (-0.29%)
     
  • CMC Crypto 200

    380.95
    +10.43 (+2.82%)
     
  • FTSE 100

    6,380.76
    -51.41 (-0.80%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

New Trends in Healthcare Push Stocks Higher: 5 Picks

Recently concluded mid-term elections have provided a much needed boost to the healthcare sector. New trends that the majority of healthcare companies are working on are also boosting the sector. In fact, the Health Care Select Sector SPDR (XLV) has outperformed the S&P 500 in the past six months.

Additionally, healthcare is a sector that could witness growth despite a global slowdown or an economic breakdown because these factors have no effect on health issues or diseases. Therefore, it might be prudent to invest in a few healthcare stocks to benefit from the tailwinds the sector is experiencing.

Healthcare Stocks Poised for Gains

Healthcare stocks will benefit from Democrats taking control of the House of Representatives, following the recently concluded mid-term elections. A divided control of Congress is undoubtedly favorable for the healthcare sector as it indicates the continued existence of Obama-era health care laws.

Health-insurer stocks such as Humana HUM and Anthem ANTM will benefit from such an outcome.  Also, drug price cuts are unlikely to pass both houses, a favorable outcome for drug companies.

Healthcare stocks have gained some traction in the second half of this year, having underperformed the market for nearly three years. Health Care Select Sector SPDR has gained more than 7% against the Dow Jones Industrial Average over the past six months, making a comeback to the highs witnessed in mid-October.

Latest Trends in Healthcare Moving Markets

The new trends in healthcare sector have gained investors’ attention who are now focusing on companies that have taken a different approach to combine human skills with emerging technologies. Companies such as Synthetic Biologics, Inc. SYN are developing treatments designed to safeguard the microbiome to improve patient health.

Several healthcare companies are also collaborating with corporate giants such as International Business Machines Corporation IBM, NVIDIA Corporation NVDA and Google Inc. GOOGL to implement artificial intelligence in the process of developing therapeutics. 

5 Medical Stocks to Buy

Given the prospects of healthcare stocks soaring higher, we have handpicked a few stocks from the sector that carry a Zacks Rank #1 (Strong Buy) or #2 (Buy).

Molina Healthcare MOH is a multi-state healthcare organization and offers a wide range of quality healthcare services. The company carries a Zacks Rank #1.

Molina Healthcare’s expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the company’s current-year earnings has advanced 22% in the past 60 days.

Anthem is a provider of health insurance plans and carries a Zacks Rank #2. The company’s expected earnings growth rate for the current year is 30% compared with the Zacks Medical - HMOs industry’s projected rise of 19.7%. The Zacks Consensus Estimate for the company’s current-year earnings has risen 1.1% in the past 60 days.

Humana provides a broad range of health insurance plans and carries a Zacks Rank #2. The company’s expected earnings growth rate for the current year is 23.3% compared with the Zacks Medical - HMOs industry’s projected rise of 19.7%. The Zacks Consensus Estimate for the company’s current-year earnings has increased 1.8% in the past 60 days.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Johnson & Johnson JNJ is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The company is trying out artificial intelligence to smoothen its drug discovery process. The company carries a Zacks Rank #2. The Zacks Consensus Estimate for the company’s current-year earnings has increased 0.2% in the past 60 days.

Merck & Co. MRK is a leading global biopharmaceutical company that is exploring the potential of artificial intelligence to streamline their process of drug discovery. The company carries a Zacks Rank #2. The Zacks Consensus Estimate for the company’s current-year earnings has increased 1.6% in the past 60 days.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
International Business Machines Corporation (IBM) : Free Stock Analysis Report
 
Alphabet Inc. (GOOGL) : Free Stock Analysis Report
 
Johnson & Johnson (JNJ) : Free Stock Analysis Report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
Synthetic Biologics, Inc (SYN) : Free Stock Analysis Report
 
Molina Healthcare, Inc (MOH) : Free Stock Analysis Report
 
Anthem, Inc. (ANTM) : Free Stock Analysis Report
 
Humana Inc. (HUM) : Free Stock Analysis Report
 
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.